RECURSION PHARMACEUTICALS INC CLAS (RXRX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RXRX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RXRX | Chair of the Board | 43 | ["Co-founder of the Company","Former Chief Executive Officer","M.D./Ph.D. student at the University of Utah","Undergraduate degrees in bioengineering (B.S.) and managerial studies (B.A.) from Rice University","Board member of Pacific Biosciences of California, Inc.","Board member of Cellino","Adviser to young biotechnology founders","Board member of the Salt Lake Tribune","Co-author of peer-reviewed studies in various journals"] | ["Research and Development","Technology","Corporate Social Responsibility"] | 2026 |
Biography sourced from the proxy statement filing.
Christopher Gibson, Ph.D., is our co-founder and Chair of the Board, as of January 1, 2026. From 2013 through 2025, Dr. Gibson served as Chief Executive Officer of the Company. Previously, Dr. Gibson was an M.D./Ph.D. student at the University of Utah. After obtaining his Ph.D., he withdrew from medical school to found Recursion. He has undergraduate degrees in bioengineering (B.S.) and managerial studies (B.A.) from Rice University. Dr. Gibson currently serves on the board of directors of Pacific Biosciences of California, Inc., since March 2026. He is also on the board of Cellino, a private cell-therapy technology company and informally advises dozens of young biotechnology founders. He is also a Board member of the Salt Lake Tribune, one of the nation s first not-for-profit newspapers. Dr. Gibson is co-author of more than a dozen peer-reviewed studies in a variety of journals including Nature, Nature Protocols, Circulation, and the Journal of Clinical Investigation. Dr. Gibson is not standing for re-election and his current term will expire at the Annual Meeting. The Board extends its sincere gratitude and appreciation to Dr. Gibson for his steadfast service, leadership, and dedication to the Company since the very beginning.